Francesca Belouad, MA, is a Research Psychologist in GEB-SDGE. She is responsible for administrating interviews and overseeing clinical aspects of the NIMH Family Study. Francesca has been employed as a Research Psychologist at the NIMH since 2000, when she was recruited by Dennis Charney, MD, during the formation of the Mood and Anxiety Disorders Research Program. Prior to this, she held research positions at the Section on Development Psychology at the NIMH, Outpatient Psychiatry at the Washington Veterans Medical Center, and the Department of Medical and Clinical Psychology at the Uniformed Services University of the Health Sciences.
Francesca s work has focused on the writing and submission of the original NIMH Family Study protocol and the development and selection of research measures. She currently administers headache, psychiatric, sleep, and family history interviews to adults and children at initial and follow-up time points. She conducts reviews of clinical assessments a
ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021
-
ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women s reproductive health, today announced the presentation of five e-Posters on linzagolix in the treatment of uterine fibroids at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM), which will take place virtually from April 30 to May 2, 2021.
The data presented further substantiate the best-in-class potential of linzagolix for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids addressing both key efficacy and safety parameters from the PRIMROSE Phase 3 program.
I
mpact of linzagolix treatment on anemia in women with uterine fibroid related heavy menstrual bleeding: results of two
P
hase 3 clinical trials
Lead author: William Catherino, MD, PhD; Professor, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences
Key Conclusions: High and low linzagolix doses with and without ABT improved hemoglobin and ferritin levels in anemic women with uterine fibroids. In the 12-week follow-up period hemoglobin levels decreased but did not return to baseline levels.
Poster
:
Safety of linzagolix in the treatment of women with uterine fibroids: Results from two Phase 3 clinical trials
Lead author: Hugh Taylor, MD; Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine